PLP-M inhibitors are a class of chemical compounds that target pyridoxal phosphate-dependent enzyme M (PLP-M), an enzyme essential for catalyzing various biochemical reactions, particularly those involved in amino acid metabolism. Like other enzymes in the PLP-dependent family, PLP-M utilizes pyridoxal 5'-phosphate (PLP) as a cofactor to carry out key reactions such as transamination, decarboxylation, and racemization. These reactions are critical for the synthesis, transformation, and degradation of amino acids, which serve as building blocks for proteins and participate in important cellular functions like nitrogen metabolism, neurotransmitter production, and cellular energy cycles. Inhibiting PLP-M disrupts these reactions, affecting amino acid-related pathways that are essential for maintaining metabolic balance and cellular function.
The mechanism of action for PLP-M inhibitors involves binding to the active site of the enzyme or interfering with its interaction with pyridoxal phosphate, preventing the enzyme from catalyzing its usual biochemical transformations. By blocking the enzymatic activity of PLP-M, these inhibitors interfere with processes like amino acid synthesis and breakdown, which can lead to changes in metabolic pathways that regulate protein production, cellular energy, and communication. Researchers utilize PLP-M inhibitors to explore the specific role of PLP-M in cellular metabolism and to understand how disruptions in this enzyme's function affect broader metabolic networks. By studying PLP-M inhibition, scientists gain insights into the importance of PLP-dependent enzymes in managing the intricate balance of amino acid transformations and their impact on cellular processes, contributing to a better understanding of how amino acid metabolism integrates into overall cellular and organismal health.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D inhibits RNA synthesis, potentially impacting the expression of PLP-M at the transcriptional level. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide inhibits RNA polymerase and NF-κB, potentially affecting the transcription of PLP-M and its regulatory pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases, potentially affecting the transcriptional regulation of PLP-M and its associated pathways. | ||||||
Triamcinolone acetonide | 76-25-5 | sc-205872 sc-205872A | 50 mg 250 mg | $56.00 $149.00 | ||
Triamcinolone acetonide is a glucocorticoid receptor agonist, and its modulation of transcriptional activity may impact the expression of PLP-M. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, potentially impacting the transcription of PLP-M and its downstream targets. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, potentially impacting the epigenetic regulation of PLP-M expression. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $142.00 $558.00 | 4 | |
Ellipticine is a DNA-intercalating agent, potentially impacting the transcriptional regulation of PLP-M and its associated pathways. | ||||||